indomethacin and Head and Neck Neoplasms studies

Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.

Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)

Research Excerpts

Excerpt	Relevance	Reference
"The efficacy and safety of indomethacin (IM) oral spray (OS) as a pain control therapy for oropharyngeal mucositis due to anticancer chemo- and radiotherapy were assessed in patients with head and neck carcinomas and haematological tumours."	9.24	Assessment of indomethacin oral spray for the treatment of oropharyngeal mucositis-induced pain during anticancer therapy. ( Bukawa, H; Chiba, S; Homma, M; Kizawa, Y; Kohda, Y; Momo, K; Nagaoka, H, 2017)
"The efficacy and safety of indomethacin (IM) oral spray (OS) as a pain control therapy for oropharyngeal mucositis due to anticancer chemo- and radiotherapy were assessed in patients with head and neck carcinomas and haematological tumours."	5.24	Assessment of indomethacin oral spray for the treatment of oropharyngeal mucositis-induced pain during anticancer therapy. ( Bukawa, H; Chiba, S; Homma, M; Kizawa, Y; Kohda, Y; Momo, K; Nagaoka, H, 2017)
"A total of 13 patients with advanced disease were enrolled in the safety/intent-to-treat population; all experienced treatment-emergent adverse events (AEs)."	2.76	A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck. ( Baltzer, L; Brandwein, HJ; Franco, JL; Freeman, SM; Hadden, JW; Kenady, DE; Roth, Z, 2011)
"A Phase II trial in 42 patients with squamous cell cancer of the head and neck (H and NSCC) was performed using a combination immunotherapy with 10-20 days of perilymphatic injections of a natural cytokine mixture (NCM: IRX-2; 200 units IL-2 equivalence) preceded by low dose cyclophosphamide (CY; 300 mg/m(2)) and followed by daily oral indomethacin (25 mg t."	2.71	A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck. ( Barrera, JL; de la Garza, J; Hadden, E; Hadden, J; Kurman, M; Meneses, A; Verastegui, E; Zinser, JW, 2003)
"Thirteen patients with advanced squamous cell carcinoma of the head and neck region."	2.69	Histologic findings in patients with head and neck squamous cell carcinoma receiving perilymphatic natural cytokine mixture (IRX-2) prior to surgery. ( Barrera, JL; de la Garza, J; Hadden, JW; Meneses, A; Verastegui, E; Zinser, J, 1998)
"Indomethacin has been shown clinically to inhibit growth of SCCHN (Panje, 1981)."	2.40	Tumor infiltrating lymphocytes in squamous cell carcinoma of the head and neck: mechanisms of enhancement using prostaglandin synthetase inhibitors. ( Adams, GL; Bach, FH; Cross, DS; Juhn, SK; Platt, JL, 1997)
"Indomethacin was able to inhibit paclitaxel-mediated NF-κB activation and promote apoptosis of paclitaxel-treated cells at 24 hours."	1.37	The effect of indomethacin on paclitaxel sensitivity and apoptosis in oral squamous carcinoma cells: the role of nuclear factor-κB inhibition. ( Caicedo-Granados, EE; Lee, GS; Marker, PH; Ondrey, FG; Wuertz, BR, 2011)
"The reasons for referral were hydrops (2), cardiomegaly (1), polyhydramnios and choroid plexus cyst (1), and polyhydramnios and teratoma of the neck (1)."	1.30	Isolated ductal closure in utero diagnosed by fetal echocardiography. ( Cavallé-Garrido, T; Farine, D; Heilbut, M; Leal, SD; Ryan, G; Smallhorn, JF, 1997)
"In a separate group of 17 patients with squamous cell carcinoma of the head and neck, tumor cells were isolated from fresh tumor specimens, and 24-hour PGE2 production in vitro was assayed."	1.29	Comparison of in vivo and in vitro prostaglandin E2 production by squamous cell carcinoma of the head and neck. ( Heo, DS; Johnson, JT; Klapan, I; Milanovich, M; Schwartz, D; Snyderman, CH; Wagner, R; Whiteside, TL, 1994)
"Metastatic squamous cell head and neck cancer was treated in four patients with low-dose cyclophosphamide (to reduce suppressor T-cell activity), indomethacin (to reduce prostaglandins that mediate macrophage-induced immune suppression), zinc (to augment T-cell function via thymulin), and mixed natural interleukins perilymphatically in the neck (as adjuvant for tumor antigen in the region)."	1.29	Interleukins and contrasuppression induce immune regression of head and neck cancer. ( Baekey, P; Endicott, J; Hadden, EM; Hadden, JW; Skipper, P, 1994)
"The tongue derived squamous carcinoma cell line, SCC-25, was treated with three leukotriene synthesis inhibitors and indomethacin."	1.29	Inhibition of head and neck tumor cell growth with arachidonic acid metabolism inhibition. ( Adams, GL; Juhn, SK; Ondrey, FG, 1996)
"When 12 patients with basal and/or squamous cell carcinomas of the facial areas were studied, the macrophages from 2 of these patients possessed cytotoxic macrophages."	1.27	The ability of macrophages from head and neck cancer patients to kill tumor cells. Effect of prostaglandin inhibitors on cytotoxicity. ( Cameron, DJ; Stromberg, BV, 1984)
"In vitro bone resorption and prostaglandin release does not correlate with pathological features of the tumour or with post-operative survival."	1.27	Further observations on mechanisms of bone destruction by squamous carcinomas of the head and neck: the role of host stroma. ( Burman, JF; Carter, RL; Pittam, MR; Tsao, SW, 1983)
"Monocytes from patients with head and neck cancer produce excessive PGE2 which seems to be associated with decreased lymphoproliferation in vitro."	1.27	Deficient immunity in head and neck cancer due to excessive monocyte production of prostaglandins. ( Berlinger, NT, 1984)
"Ten patients with terminal squamous cell carcinoma of the head and neck were treated with indomethacin, and inhibitor of PG synthesis."	1.27	Immunostimulation of patients with head and neck cancer. In vitro and preliminary clinical experiences. ( Hirsch, B; Johnson, JT; Rabin, BS; Thearle, PB, 1983)
"In a prospective study of squamous head and neck cancer, the pretreatment peripheral blood of 125 patients was examined for lymphocyte subclass and in vitro immunologic function."	1.27	A prospective study of squamous head and neck carcinoma. Immunologic aberrations in patients who develop recurrent disease. ( Brantley, BA; Cole, TB; Crocker, IR; Fisher, SR; Huang, AT; Mold, NG; Wallman, MJ, 1987)
"Head and neck cancer (H&N CA) patients have known depression of cell-mediated immunity."	1.27	Indomethacin sensitive suppressor-cell activity in head and neck cancer patients. The role of the adherent mononuclear cell. ( Cantrell, RW; Johns, ME; Katz, D; Pace, RC; Riley, T; Wanebo, HJ, 1988)
"Patients with epidermoid cancer of the head and neck thus have an abnormality of immunoregulatory monocytes that can contribute significantly to their depression of cellular immunity by elaborating prostaglandin E2."	1.26	Excessive prostaglandin E2 production by suppressor monocytes in head and neck cancer patients. ( Balch, CM; Dougherty, PA; Tilden, AB, 1982)

Research

Studies (36)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Number of Participants With High Lymphocyte Infiltration (LI) According to the Visual Analog Scale (VAS)

Timeframe	Studies, this research(%)	All Research%
pre-1990	14 (38.89)	18.7374
1990's	9 (25.00)	18.2507
2000's	7 (19.44)	29.6817
2010's	5 (13.89)	24.3611
2020's	1 (2.78)	2.80

Authors	Studies
Nagaoka, H	2
Momo, K	2
Hamano, J	1
Miyaji, T	1
Oyamada, S	1
Kawaguchi, T	1
Homma, M	2
Yamaguchi, T	1
Morita, T	1
Kizawa, Y	2
Bukawa, H	1
Chiba, S	1
Kohda, Y	1
Freeman, SM	2
Franco, JL	1
Kenady, DE	2
Baltzer, L	2
Roth, Z	1
Brandwein, HJ	2
Hadden, JW	6
Wolf, GT	1
Fee, WE	1
Dolan, RW	1
Moyer, JS	1
Kaplan, MJ	1
Spring, PM	1
Suen, J	1
Newman, JG	1
Carroll, WR	1
Gillespie, MB	1
Kirkley, TD	1
Ogura, K	1
Shinoda, Y	1
Okuma, T	1
Ushiku, T	1
Motoi, T	1
Kawano, H	1
Caicedo-Granados, EE	1
Wuertz, BR	1
Marker, PH	1
Lee, GS	1
Ondrey, FG	2
Lang, S	1
Lauffer, L	1
Clausen, C	1
Löhr, I	1
Schmitt, B	1
Hölzel, D	1
Wollenberg, B	1
Gires, O	1
Kastenbauer, E	1
Zeidler, R	1
Hadden, J	1
Verastegui, E	4
Barrera, JL	4
Kurman, M	1
Meneses, A	4
Zinser, JW	1
de la Garza, J	4
Hadden, E	1
Feinmesser, R	1
Hardy, B	1
Sadov, R	1
Shwartz, A	1
Chretien, P	1
Feinmesser, M	1
Pelzmann, M	1
Thurnher, D	2
Gedlicka, C	1
Martinek, H	1
Knerer, B	2
Balch, CM	1
Dougherty, PA	1
Tilden, AB	1
Cameron, DJ	1
Stromberg, BV	1
Tsao, SW	2
Burman, JF	2
Pittam, MR	1
Carter, RL	2
Berlinger, NT	1
Hirsch, B	1
Johnson, JT	2
Rabin, BS	1
Thearle, PB	1
Maca, RD	1
Panje, WR	3
Easty, DM	1
Easty, GC	1
Snyderman, CH	1
Klapan, I	1
Milanovich, M	1
Heo, DS	1
Wagner, R	1
Schwartz, D	1
Whiteside, TL	1
Endicott, J	1
Baekey, P	1
Skipper, P	1
Hadden, EM	1
Juhn, SK	3
Adams, GL	3
Leal, SD	1
Cavallé-Garrido, T	1
Ryan, G	1
Farine, D	1
Heilbut, M	1
Smallhorn, JF	1
Cross, DS	2
Platt, JL	2
Bach, FH	2
Zinser, J	2
Sugihara, T	1
Hattori, Y	1
Yamamoto, Y	1
Qi, F	1
Ichikawa, R	1
Sato, A	1
Liu, MY	1
Abe, K	1
Kanno, M	1
Bakroeva, M	1
Formanek, M	1
Kornfehl, J	1
Lapointe, H	1
Lampe, H	1
Banerjee, D	1
Huang, AT	1
Mold, NG	1
Fisher, SR	1
Brantley, BA	1
Cole, TB	1
Wallman, MJ	1
Crocker, IR	1
Wanebo, HJ	1
Riley, T	1
Katz, D	1
Pace, RC	1
Johns, ME	1
Cantrell, RW	1
Stiernberg, CM	1
Rotzler, WH	1
Valyi-Nagy, K	1
Hokanson, JA	1
Hale, PE	1
Williamson, A	1
Miller, RH	1
McCormick, KJ	1
Pillsbury, HC	1
Webster, WP	1
Rosenman, J	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 2, Open-label Trial of the Safety and Biological Effect of Subcutaneous IRX-2 (With Cyclophosphamide, Indomethacin, and Zinc) in Patients With Resectable Cancer of the Head and Neck[NCT00210470]	Phase 2	27 participants (Actual)	Interventional	2005-07-31	Completed
A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy With the IRX 2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity[NCT02609386]	Phase 2	105 participants (Actual)	Interventional	2015-12-31	Completed
Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971]	Phase 1/Phase 2	30 participants (Actual)	Interventional	2002-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"Immunologic response features were extracted and quantified using a VAS of 0-100 mm to provide for a more continuous variable than the 0-4+ scale that is often used to assess histological responses. The scoring was such that 100 represented the maximum for any sample and 0 represented the lack of any parameter of interest.~See publication of Berinstein, et al., 2012 for complete details." (NCT00210470)
Timeframe: On approximately Day 21 (last day of treatment) prior to undergoing post-treatment surgery

Relationship Between Overall Survival (OS) and Immune Competence (Lymphocyte Infiltration, LI) in Participants With High LI and Low LI

Intervention	participants with high LI (>34 mm) VAS (Number)
IRX-2 Regimen	18

"After participants completed the IRX-2 regimen and the tumor resection was performed, tumor pathology was evaluated from tissue specimens obtained at tumor resection. Formalin-fixed, paraffin-embedded blocks, or unstained slides from the primary tumor were submitted to an independent pathology laboratory for hematoxylin and eosin staining, and evaluation of lymphocyte infiltration (LI). Participants were grouped into a low LI and high LI group based on the change in lymphocyte infiltration from the pretreatment tumor biopsy to the post-treatment tumor surgical resection. 5-year overall survival probabilities were then estimated (Kaplan-Meier) between the low LI and high LI groups" (NCT00210470)
Timeframe: At time of surgery, after treatment with IRX-2 Regimen, assessed up to 5 years

Clinical and Histological Tumor Responses

Intervention	5-Year OS Probability (Number)
High Lymphocyte Infiltration (LI)	0.80
Low Lymphocyte Infiltration	0.50

Number of participants with the specified percent change in size of target lesion is presented (NCT00210470)
Timeframe: On approximately Day 21 (last day of treatment) prior to undergoing post-treatment surgery

Disease-free Survival

Intervention	Participants (Count of Participants)
	-20% to < -10%	-10% to < 0%	0% to < 10%	10% to < 20%	20% to < 30%	>= 30%
IRX-2 Regimen	4	7	9	1	0	2

Estimate disease-free survival (DFS) (time from surgery to death or clinically apparent, biopsy confirmed recurrent or progressive disease after the completion of initial therapy, assessed up to 3 years; margins of resection positive for tumor will not be considered disease recurrence). (NCT00210470)
Timeframe: Time from surgery to death or clinically apparent, biopsy confirmed recurrent or progressive disease after the completion of initial therapy, assessed up to 3 years; margins of resection positive for tumor will not be considered disease recurrence

Immune Competence as Measured by Skin Test Reactivity

Intervention	DFS Probability (Number)
	1-year disease free survival probability	2-year disease free survival probability	3-year disease free survival probability
IRX-2 Regimen	0.721	0.641	0.620

To assess measures of immune competence following administration of the IRX-2 regimen, including skin test reactivity. (NCT00210470)
Timeframe: At approx. 21 days, prior to surgery

Number of Participants With Adverse Events and Serious Adverse Events

Intervention	Participants (Count of Participants)
	Positive at both Baseline and at Day 21 (%)	Negative at both Baseline and Day 21 (%)	Positive at Baseline and Negative Day 21 (%)	Negative at Baseline and Positive at Day 21	Induration at Day 21
IRX-2 Regimen	12	6	6	2	3

The frequency of all Adverse Events (greater than 5%) is reported. All Serious Adverse Events were described. (NCT00210470)
Timeframe: Enrollment through 30 days post-surgery

Overall Survival

Intervention	Participants (Count of Participants)
	Adverse Event: Injection Site Pain	Adverse Event: Headache	Adverse Event: Nausea	Adverse Event: Constipation	Adverse Event: Dizziness	Adverse Event: Fatigue	Adverse Event: Pneumonia Aspiration	Adverse Event: Anaemia	Adverse Event: Injection Site Discomfort	Adverse Event: Myalgia	Adverse Event: Contusion	Adverse Event: Dry Mouth	Adverse Event: Vomiting	Additional AE Categories w lower frequency	Serious Adverse Events
IRX-2 Regimen	6	8	6	4	4	3	3	3	3	2	2	2	2	4	7

Estimate overall survival (OS) in patients receiving the IRX-2 regimen. IRX-2 is currently being studied in an on-going Phase 2b clinical trial in patients with newly diagnosed Stage II, III, and IVA squamous cell carcinoma of the oral cavity (INSPIRE) (NCT00210470)
Timeframe: Time from surgery to death or confirmed recurrent or progressive disease, assessed up to 3 years

Patient Tolerance of Surgery and Post-operative Adjuvant Therapy;

Intervention	percentage of subjects (Number)
	First Year (%)	Second Year (%)	Third Year (%)
IRX-2 Regimen	92	73	69

Patient Tolerance of Surgery and Post-operative Adjuvant Therapy as measured by median days spent in the hospital, intensive care unit, and step down unit. (NCT00210470)
Timeframe: Following surgery and post-operative therapy (up to 39 days post surgery)

Response as Evaluated by Recurrence of Diseases

Intervention	days (Median)
	Median Days in hospital	Median Days in intensive care unit	Median Days in step-down unit
IRX-2 Regimen	8.5	0.5	0.5

Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)

Toxicity of Celecoxib With Concurrent Weekly Chemotherapy and Radiotherapy in the Treatment of Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck.

Intervention	Participants (Number)
	Local Control Only	Local Control and Distant Metastasis	Distant Metastatsis Only	Secondary Primary - Site Unknown	Surgical Salvage
Recurrence	6	2	1	2	3

Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy

Intervention	participants (Number)
	Hematologic	Dermatitis	Mucositis/Dysphagia
Acute Toxicity	12	7	16

Article	Year
Effects of an Indomethacin Oral Spray on Pain Due to Oral Mucositis in Cancer Patients Treated With Radiotherapy and Chemotherapy: A Double-Blind, Randomized, Placebo-Controlled Trial (JORTC-PAL04). Journal of pain and symptom management, 2021, Volume: 62, Issue:3 Topics: Adult; Double-Blind Method; Head and Neck Neoplasms; Humans; Indomethacin; Oral Sprays; Pain; Qualit	2021
Assessment of indomethacin oral spray for the treatment of oropharyngeal mucositis-induced pain during anticancer therapy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2017, Volume: 25, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Female; Head an	2017
A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck. American journal of clinical oncology, 2011, Volume: 34, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cyclophospham	2011
Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head & neck, 2011, Volume: 33, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Cytokines; Disease-F	2011
Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head & neck, 2011, Volume: 33, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Cytokines; Disease-F	2011
Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head & neck, 2011, Volume: 33, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Cytokines; Disease-F	2011
Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head & neck, 2011, Volume: 33, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Cytokines; Disease-F	2011
A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck. International immunopharmacology, 2003, Volume: 3, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cy	2003
Report of a clinical trial in 12 patients with head and neck cancer treated intratumorally and peritumorally with multikine. Archives of otolaryngology--head & neck surgery, 2003, Volume: 129, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Therapy, Combinatio	2003
Histologic findings in patients with head and neck squamous cell carcinoma receiving perilymphatic natural cytokine mixture (IRX-2) prior to surgery. Archives of pathology & laboratory medicine, 1998, Volume: 122, Issue:5 Topics: Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cyclophosphamide; Cytokines; Drug Combinatio	1998
Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial. Archives of otolaryngology--head & neck surgery, 2000, Volume: 126, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Combined Modality Therapy; Cyclophosphamid	2000
Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Archives of otolaryngology--head & neck surgery, 1986, Volume: 112, Issue:5 Topics: Clinical Trials as Topic; Combined Modality Therapy; Double-Blind Method; Head and Neck Neoplasms; H	1986

Article	Year
Recurrent epithelioid hemangioma: therapeutic potential of tranilast and indomethacin. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2012, Volume: 17, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Diagnosis, Differential; Dose-Response Relat	2012
The effect of indomethacin on paclitaxel sensitivity and apoptosis in oral squamous carcinoma cells: the role of nuclear factor-κB inhibition. Archives of otolaryngology--head & neck surgery, 2011, Volume: 137, Issue:8 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor	2011
Impaired monocyte function in cancer patients: restoration with a cyclooxygenase-2 inhibitor. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2003, Volume: 17, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Squamous Cell; Cell Movement; Cyclooxyg	2003
Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2. International immunopharmacology, 2003, Volume: 3, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva	2003
Nimesulide and indomethacin induce apoptosis in head and neck cancer cells. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2004, Volume: 33, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cel	2004
Excessive prostaglandin E2 production by suppressor monocytes in head and neck cancer patients. Annals of surgery, 1982, Volume: 196, Issue:6 Topics: Adult; Aged; Carbazoles; Carcinoma, Squamous Cell; Dinoprostone; Head and Neck Neoplasms; Humans; In	1982
The ability of macrophages from head and neck cancer patients to kill tumor cells. Effect of prostaglandin inhibitors on cytotoxicity. Cancer, 1984, Dec-01, Volume: 54, Issue:11 Topics: Carcinoma, Squamous Cell; Cell Line; Cytotoxicity, Immunologic; Facial Neoplasms; Female; Head and N	1984
Further observations on mechanisms of bone destruction by squamous carcinomas of the head and neck: the role of host stroma. British journal of cancer, 1983, Volume: 48, Issue:5 Topics: Animals; Bone Resorption; Carcinoma, Squamous Cell; Cell Line; Culture Media; Culture Techniques; Di	1983
Deficient immunity in head and neck cancer due to excessive monocyte production of prostaglandins. The Laryngoscope, 1984, Volume: 94, Issue:11 Pt 1 Topics: Aged; Dinoprostone; Head and Neck Neoplasms; Humans; Immunity, Cellular; Indomethacin; Lymphocyte Ac	1984
Immunostimulation of patients with head and neck cancer. In vitro and preliminary clinical experiences. Archives of otolaryngology (Chicago, Ill. : 1960), 1983, Volume: 109, Issue:5 Topics: Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Immunity, Cellular; Indomethacin; Lymphoc	1983
Indomethacin sensitive suppressor cell activity in head and neck cancer patients pre- and postirradiation therapy. Cancer, 1982, Aug-01, Volume: 50, Issue:3 Topics: Carcinoma, Squamous Cell; Concanavalin A; Head and Neck Neoplasms; Humans; Indomethacin; Lymphocyte	1982
Some mechanisms of local bone destruction by squamous carcinomas of the head and neck. British journal of cancer, 1981, Volume: 43, Issue:3 Topics: Adult; Animals; Bone Resorption; Carcinoma, Squamous Cell; Cell Line; Female; Head and Neck Neoplasm	1981
Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Archives of otolaryngology (Chicago, Ill. : 1960), 1981, Volume: 107, Issue:11 Topics: Adult; Aged; Biopsy; Bone and Bones; Bone Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Head and N	1981
Comparison of in vivo and in vitro prostaglandin E2 production by squamous cell carcinoma of the head and neck. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 1994, Volume: 111, Issue:3 Pt 1 Topics: Aged; Aged, 80 and over; Blood; Carcinoma, Squamous Cell; Cell Line; Culture Media; Dinoprostone; Do	1994
Interleukins and contrasuppression induce immune regression of head and neck cancer. Archives of otolaryngology--head & neck surgery, 1994, Volume: 120, Issue:4 Topics: Adult; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Therapy, Combination; Head and Neck Neoplasm	1994
Inhibition of head and neck tumor cell growth with arachidonic acid metabolism inhibition. The Laryngoscope, 1996, Volume: 106, Issue:2 Pt 1 Topics: Arachidonic Acid; Carcinoma, Squamous Cell; Cell Division; Cyclooxygenase Inhibitors; Head and Neck	1996
Isolated ductal closure in utero diagnosed by fetal echocardiography. American journal of perinatology, 1997, Volume: 14, Issue:4 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiomegaly; Choroid Plexus; Cysts; Ductus Arterios	1997
Preferential impairment of nitric oxide-mediated endothelium-dependent relaxation in human cervical arteries after irradiation. Circulation, 1999, Aug-10, Volume: 100, Issue:6 Topics: Acetylcholine; Adult; Aged; Arteries; Calcimycin; Combined Modality Therapy; Cyclooxygenase Inhibito	1999
Non-steroidal anti-inflammatory drugs inhibit telomerase activity in head and neck squamous carcinoma cell lines. Head & neck, 2001, Volume: 23, Issue:12 Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma,	2001
Administration of a prostaglandin synthetase inhibitor associated with an increased immune cell infiltrate in squamous cell carcinoma of the head and neck. Archives of otolaryngology--head & neck surgery, 1992, Volume: 118, Issue:5 Topics: Aged; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Indomethacin; Lymphocytes, Tumor-In	1992
Head and neck squamous cell carcinoma cell line-induced suppression of in vitro lymphocyte proliferative responses. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 1992, Volume: 106, Issue:2 Topics: Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Immune Tolerance; Immunity, Cellular; Ind	1992
A prospective study of squamous head and neck carcinoma. Immunologic aberrations in patients who develop recurrent disease. Cancer, 1987, May-15, Volume: 59, Issue:10 Topics: Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Indomethacin; Interleukin-2; Lymphocyte A	1987
Indomethacin sensitive suppressor-cell activity in head and neck cancer patients. The role of the adherent mononuclear cell. Cancer, 1988, Feb-01, Volume: 61, Issue:3 Topics: Adult; Aged; Aging; Female; Head and Neck Neoplasms; Humans; Immunity, Cellular; Indomethacin; Male;	1988
Subrenal capsule assay for squamous cell carcinoma of the head and neck. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 1986, Volume: 95, Issue:2 Topics: Animals; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Head and Neck Neoplasms; Humans; Indo	1986
Immunotherapy of head and neck cancer: an overview. The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society, 1988, Volume: 140, Issue:4 Topics: Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Cimetidine; Head and Neck Neoplasms; Humans;	1988
Indomethacin-induced augmentation of lymphoproliferative responses in patients with head and neck cancer. Cancer immunology, immunotherapy : CII, 1986, Volume: 21, Issue:3 Topics: Adult; Aged; Carbazoles; Carcinoma, Squamous Cell; Dinoprostone; Esterases; Head and Neck Neoplasms;	1986

indomethacin and Head and Neck Neoplasms